Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs and FX are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs and FX are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
AskTraders may earn a commission when you click through to a broker.
Zymeworks Licenses Lung Cancer Drug to Roche
Zymeworks has licensed its experimental lung cancer drug ZW209 to Roche in a deal worth up to $813m, but only $95m is near-term and the rest depends on clinical success.
Zymeworks (NASDAQ: ZYME), the cancer drug developer, has licensed its experimental lung cancer drug ZW209 to Roche in a deal worth up to $813m. The company announced the exclusive global licence and collaboration agreement at 11am UK time today, before the US open.
The shares have not yet traded on the news. The last price is yesterday’s close of $28.44, up 1.156% on the session before and 14.8% above the $24.77 close on the 14th of October, a rise that came before the announcement.
ZW209 is a T cell engager, a drug that steers the body’s T cells towards cancer cells, aimed at DLL3, a protein found on small cell lung cancer. Zymeworks will run the Phase 1a monotherapy trial, which Roche funds, and Roche then takes over global development and commercialisation. The US regulator has cleared the drug’s investigational application.
Sponsored content
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The $813m headline is our sum of three pieces: $55m upfront, $40m when the Phase 1b trial starts, and up to $718m of further development, commercial and sales milestones. Tiered royalties, from high single digit to mid-teen percent of global net sales, come on top. Patents run into the 2040s. The deal is also subject to expiry of the US antitrust waiting period under the Hart-Scott-Rodino Act.
Only $95m is near-term, and $40m of that is conditional on the Phase 1b start. By our calculation, $55m is about 2.7% and $95m about 4.7% of Zymeworks’ market value of roughly $2.0bn at yesterday’s close. Trailing twelve-month revenue is $37.127m.
Zymeworks (ZYME.US) daily close, 20 July to 22 October 2026, US dollars. The Roche deal came after the last close shown.
Boris L. Zaïtra, Head of Corporate Business Development at Roche, the Swiss drugmaker, said of the drug:
Sponsored
ZW209 represents an innovative approach that complements our ongoing efforts to develop new treatment options for people living with lung cancer.
Boris L. Zaïtra, Roche
Zymeworks holds an investor call on Tuesday at 8:30am ET.
The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.
Stay ahead of the markets
Sign up to our free Morning Markets email, every weekday before the open.
Stay ahead of the markets
Morning Markets
Weekdays
FTSE, overnight moves and what matters before the open.
Show personalised advertising and content, and measure how adverts and content perform
Learn about our audience and develop and improve our services
Learn more
Advertising pays for our free market news, analysis and trading tools.
If you accept, we and our partners may also match and combine data from other sources, link your devices, and identify your device from its characteristics, precise location or by actively scanning it. Some partners rely on legitimate interest rather than consent for certain purposes; you can object in the full list.
You can reject, or choose which purposes to allow under Manage options. Your choice is kept for this browser and you can change it at any time. See every purpose and partner
Necessary
Always active
Needed to run AskTraders and to remember your choice here. Always on.
Preferences
Remembers choices you make on AskTraders, such as display settings.
Analytics
Lets us count visits and see which pages are useful, using tools such as Google Analytics.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising and personalisation
Lets us and our advertising partners show personalised adverts and content, measure them and learn about our audience, and lets us offer web push notifications. See every purpose and partner
We and our advertising partners use cookies to show relevant advertising and measure its performance. You can opt out of the sale or sharing of your personal information, and of personalised advertising, at any time using the link below.
Necessary
Always active
Needed to run AskTraders and to remember your choice here. Always on.
Preferences
Remembers choices you make on AskTraders, such as display settings.
Analytics
Lets us count visits and see which pages are useful, using tools such as Google Analytics.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising and personalisation
Lets us and our advertising partners show personalised adverts and content, measure them and learn about our audience, and lets us offer web push notifications. See every purpose and partner
